$ cat ./records/gates-foundation-funds-galvmed-babesiosis-vaccine-research-to-com-2014.txt
Gates Foundation Funds GALVmed Babesiosis Vaccine Research to Combat Tick-Borne Cattle Disease Across Africa
[RECORD.TXT] · cat --full
Babesiosis — caused by Babesia bigemina and Babesia bovis and transmitted by Rhipicephalus (Boophilus) ticks — kills more than a million cattle annually in Africa and costs the continent billions in lost productivity. The Gates Foundation funded GALVmed to advance recombinant subunit vaccine research, aiming to replace live attenuated vaccines that carry biosafety risks and cold-chain requirements incompatible with rural African veterinary systems.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Backs Cornell Alliance for Science to Advocate Evidence-Based Agricultural Biotechnology in Africa and Asia
Next →
Gates Foundation Awards $11 Million to International Consortium to Develop East Coast Fever Vaccine
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.